Rifapentine Safety and PK with Novel Dosing Strategies to Increase Drug Exposures for TB: ACTG A5311
Background: Rifapentine (RPT) is a potent anti-tuberculosis (TB) drug poised to enter Phase 3 trials. Its sterilizing activity and treatment-shortening potential are exposure-dependent. To optimize exposures, RPT must be taken with food, and bioavailability declines with increased dose. Methodology: This phase 1, two-arm, open-label, multicenter trial in healthy HIV/TB-uninfected subjects investigated two strategies to increase…